Introduction

▼
Paclitaxel is an eff ective antineoplastic agent used extensively in the treatment of a broad spectrum of malignancies including ovarian cancer, breast cancer, and non-small cell lung cancer [ 1 ] . Because of its poor solubility in aqueous solution, the surfactant polyoxyethylated castor oil (Cremophor EL) is formulated in the commercial injection (Taxol ® ). However, this vehicle causes serious hypersensitivity reaction including vasodilation, dyspnea, and hypotension [ 2 , 3 ] , and leaches plasticizers di-(2-ethylhexyl) phthalate (DEPH) from polyvinyl chloride (PVC) containers [ 4 ] . To overcome the above problems, numerous water-soluble drug delivery systems without Cremophor EL have been investigated, such as albumin-bound formulation [ 5 ] , microemulsions [ 6 ] , porous particles [ 7 ] and polymeric micellar formulation [ 8 ] .
Liposome is a promising approach among these preparations. This vehicle is a versatile and advanced nanodelivery formulation formed by phospholipid bilayers which are able to encapsulate a variety of drugs [ 9 ] . With the aim to enhance the therapeutic effi ciency and reduce the toxicity, 
Animals
Sprague-Dawley rats (200 ± 20 g) of both genders were purchased from Nanjing Medical University Laboratory Animal Centre, and Beagle dogs (9.4 ± 0.3 kg) of both genders were off ered by Southeast University Laboratory Animal Centre. Animals were housed under controlled conditions (room temperature: 20 ± 2 °C, relative humidity: 50 ± 20 %) and accommodated to the housing environment for 1 week before the experiment. All of the animal studies were approved by the Animal Ethics Committee of China Pharmaceutical University.
Chromatographic conditions
The HPLC system (Shimadzu, Japan) comprised 2 model LC-20AD pumps, a SIL-20AD autosampler, a CBM-20 A system controller and a CTO-20 A oven. A BDS HYPERSIL C18 column (5 μm, 2.1 × 50 mm, Thermo Scientifi c) was used for separation. The mobile phase A was water phase (containing 0.1 % formic acid and 0.3 mM sodium acetate) and the mobile phase B was methanol. The analytes were eluted with a gradient mode started at 10 % mobile phase B for 1.0 min, next increased to 90 % B in 1.0 min, and maintained at 90 % B from 2.0 to 4.5 min, then decreased B to the initial percentage during 1.0 min and reequilibrated at 10 % B for 0.5 min. The fl ow rate was 0.3 mL/min, and the temperature of column was 40 °C.
Mass spectrometric conditions
Mass analysis was conducted by a Thermo Scientifi c TSQ Quantum MS/MS system equipped with electrospray ionization interface operated in the positive ionization mode. Quantifi cation was accomplished in selective reaction monitoring (SRM) by monitoring the transition of m/z 876.0→307.8 for paclitaxel and m/z 830.3→549.0 for docetaxel (the internal standard). The spray voltage, the temperature of capillary, sheath gas pressure and auxiliary gas pressure were set at 3 500 V, 350 °C, 35 Arb, 25 Arb, respectively.
Pharmacokinetic studies
Paclitaxel liposome dissolved in 5 % glucose injection solution was i. v. administrated to Sprague-Dawley rats (5 mg/kg) and Beagle dogs (1 mg/kg). About 100 μL of blood was collected via jugular vein from rats and 1 mL of blood was collected via cephalic vein from dogs into heparinized tubes at 0, 0.083, 0.167, 0.333, 0.5, 1, 2, 4, 8, 12 and 24 h, respectively. Plasma was separated by centrifuging at 4 000 rpm for 10 min and stored at − 70 °C until analysis. The paclitaxel concentrations were determined by LC-MS/MS. The estimation of pharmacokinetic parameters was performed by a non-compartmental analysis using the WinNonlin computer program (Version 4.0; Pharsight Corporation).
Biodistribution
The Sprague-Dawley rats were divided into 4 groups randomly and then received an i. v. dose (5 mg/kg) of paclitaxel liposome. Each group of rats was sacrifi ced at 0.25, 1, 4 and 12 h after intravenous injection. Tissues including liver, spleen, lung, kidney, intestine, heart, stomach, ovary, uterus, muscle, testis and brain were collected, rinsed in saline, blotted excess fl uid, weighed and sored at − 70 °C until analysis.
Plasma and tissue samples preparation
Tissue samples were homogenized in saline (tissue-water ratio of 1:3, w/v). Aliquots of the homogenate (100 μL) or plasma (50 μL) were added to a triple volume of acetonitrile containing 33.3 μg/L docetaxel (the internal standard) to precipitate proteins. The mixture was vortex-mixed for 30 s and centrifuged at 16 000 rpm for 10 min. An aliquot of 5 μL of the supernatants was injected into the LC-MS/MS system for the determination.
Results
▼
Method validation
The calibration curve with ten points was established for paclitaxel within the range from 2 to 2 000 μg/L and the lowest limit of quantifi cation was 2 μg/L. The precision and accuracy were assessed by the 5 replicates of quality control (QC) samples at low level (5 μg/L), median level (100 μg/L) and high level (1 600 μg/L). The RSDs of inter-day and intra-day precision were within 15 % of the 3 QC levels, and the accuracy extended from 85 % to 115 %. The recoveries of paclitaxel from plasma and tissue homogenate were greater than 85 %. There was no signifi cant matrix eff ect observed. The plasma pharmacokinetic characteristics of paclitaxel in rats and dogs were similar. The AUC 0-24 were 3 566.5 ± 1 366.1 and 443.2 ± 165.7 μg · h/L, CL were 1.5 ± 0.5 and 2.1 ± 0.6 L/h/kg, t 1/2 were 9.3 ± 2.9 and 14.1 ± 6.9 h, C max were 11 848.5 ± 4 413.3 and 1 087.3 ± 733.9 μg/L in rats and dogs, respectively. The pharmacokinetic parameters calculated by a non-compartmental analysis using the WinNonlin software are presented in • ▶ Table 1 .
Tissue distribution of paclitaxel liposome in rats
After intravenous administration of Lipusu at a dosage of 5 mg/ kg to Sprague-Dawley rats, the mean concentrations of paclitaxel in selected tissues at 15 min, 1 h, 4 h and 12 h are depicted in • ▶ Fig. 2 . It can be seen that after intravenous injection, liposomal paclitaxel distributed rapidly into various tissues. At 15 min post-dose, the concentrations of paclitaxel displayed maxima in most organs. The maximal concentrations of paclitaxel in spleen and liver were much higher than any other organs, followed by lung, kidney and heart. The concentrations of paclitaxel in other tissues were relatively low. Trace amount of paclitaxel was detected in brain and testis ( • ▶ Fig. 2 ).
To assess the amount of paclitaxel accumulated in each tissue, the AUC 0-12 h values were calculated and summarized in • ▶ Table 2 .
The AUC 0-12 h of each tissue in a descending order was liver > spleen > lung > kidney > intestine > heart > stomach > ovary > uterus > muscle > testis > brain.
Discussion
▼
Lipusu, the fi rst commercial paclitaxel liposome preparation, is freeze-dried powder and dissolved in 5 % glucose prior to injection. Compared with Taxol injection, the toxicity and incidence of hypersensitivity reaction after intravenous administration of Lipusu are much lower, since it is devoid of Cremophor EL and ethanol [ 12 , 13 ] . It has been reported that anaphylactic reactions are not recorded in patients with Lipusu-based chemotherapy via premedication in a clinical trial [ 14 ] . Therefore paclitaxel liposome preparation may take place of the conventional paclitaxel injection. In this work, the pharmacokinetic and biodistribution studies of paclitaxel liposome (Lipusu) have been conducted in Sprague-Dawley and Beagle dogs, which are widely-used animal models in non-clinical pharmacokinetic researches.
To determine the concentrations of the paclitaxel in biosamples, several analytical methods have been developed. Most of them involved multiple steps of sample treatment, such as liquid-liquid extraction [ 15 , 16 ] or solid-phase extraction [ 17 , 18 ] followed by evaporation and reconstitution, which are arduous, time-consuming and need a large sample volume. In present study we applied a rapid and simple LC-MS/MS method for the quantitative analysis of paclitaxel in plasma and tissues. After a simple one-step protein precipitation of biosamples with acetonitrile (biosample-acetonitrile ratio of 1 : 3, v/v), the supernatants was injected into the LC-MS/MS system for the determination. This labor-saving and high-effi ciency method is suitable for the quantifi cation of paclitaxel in pharmacokinetic researches.
After an intravenous dose, both of the plasma concentrationtime curves of paclitaxel in rats and dogs displayed bi-phasic pharmacokinetics ( • ▶ Fig. 1 ). The plasma concentrations of paclitaxel dropped markedly in the fi rst 1 h post-dose, indicating a rapid distribution phase owing to the eff ective sequestration of Table 1 Pharmacokinetic parameters of paclitaxel after intravenous administration of Lipusu in rats (5 mg/kg) and dogs (1 mg/kg), respectively (mean ± SD, n = 8). liposomes by the reticulo endothelial system (RES), and then followed by slow elimination with a long terminal phase. The interindividual variabilities in rapid distribution but not elimination phase have major contributions to the large standard deviations of pharmacokinetic parameters ( • ▶ Table 1 ), which is probably ascribed to the diff erences of RES systems among the animals. The volume of distribution (V d ) and the elimination half-life (t 1/2 ) in dogs were larger than that in rats, suggesting that paclitaxel in dogs showed more extensive tissues distribution and slower elimination by comparison to rats following intravenous administration of Lipusu. In addition, the larger V d along with the smaller dosage probably resulted in the signifi cantly lower maximal concentration (C max ) in dogs than that in rats. Considering the results of biodistribution study, it is likely that the slow elimination in terminal phase is attributed to the redistribution of paclitaxel from tissues back to plasma. It has been reported the reticulo endothelial system (RES) is a major clearance mechanism of circulation liposomes [ 19 ] . Our results showed that liposomal paclitaxel was mainly distributed to RES organs, such as liver and spleen. After i. v. bolus administration, spleen displayed the highest concentration among the selected tissues at 15 min, and followed by liver ( • ▶ Fig. 2 ). However, the AUC 0-12 h of liver is higher than spleen, for paclitaxel in liver decreased slowly and kept a higher concentration state for a long period. Similar to liver, the paclitaxel in ovary and uterus also showed slow elimination. This delayed release of liposomeencapsulated paclitaxel may result in a prolonged antitumor action time. In addition, the concentrations of paclitaxel in brain and testis were very low and around the lowest limit of quantifi cation (LLOQ) at 4 h post-dose ( • ▶ Fig. 2 ), probably due to the blood-brain barrier and the blood-testis barrier.
Pharmacokinetic Parameters Rats Dogs
In conclusion, this study revealed that liposomal paclitaxel was rapidly distributed from plasma to various organs especially spleen and liver but eliminated slowly after intravenous administration of Lipusu. Additionally, a rapid, simple and reproducible LC-MS/MS assay was established to analysis the paclitaxel concentrations. This non-clinical research off ered the disposition details of liposomal paclitaxel in vivo and may provide helps in pharmaceutical researches.
